A quantum sampler leaves the whiteboard
Drug discovery often begins with a search through more molecular possibilities than any laboratory could ever test one by one. A quantum version of a familiar sampling routine has now run on Quantinuum's H2 and Helios systems, producing accurate results on physical qubits in a tightly bounded experiment. The practical lesson is demanding rather than triumphant: useful sampling methods must survive hardware noise before any theoretical speedup can help real molecular research.
The method at the center of this work is Markov Chain Monte Carlo, a workhorse for drawing samples from complicated probability distributions. In chemistry, those distributions can describe the many configurations a molecule may adopt, and the questions that matter often reduce to an average taken over that vast space. The appeal of a quantum approach is specific and bounded: quantum amplitude estimation offers a quadratic reduction in the resources needed to estimate certain averages, provided the machine can first prepare the right probability distribution. That proviso has always been the awkward part, and it is exactly what this experiment set out to test on real hardware.
In a March 2026 preprint, Baptiste Claudon, Sergi Ramos-Calderer and Jean-Philip Piquemal encoded two-state Markov chains, prepared their stationary distributions, and ran the algorithm on Quantinuum's H2 and Helios computers, within a collaboration between the Centre for Quantum Technologies in Singapore and Qubit Pharmaceuticals. They keep the claim modest: the experiment uses the simplest non-trivial chains and tests the building blocks of the method, not a pharmaceutical molecule. That restraint is what makes it useful. It isolates the sampling machinery, shows which pieces can already survive a real device, and hands researchers something concrete to improve next: state preparation, circuit depth, error behavior, and the handoff between quantum sampling and classical analysis. For medicine, the humane stake arrives much later, after years of chemistry, toxicology and clinical work, so the near-term value is scientific discipline rather than a faster cure. A hardware run with clearly stated limits is more useful to a decision-maker than a grand promise, because it lets the field see exactly how far the computation has traveled and how far it still has to go, one reproducible step at a time.
The heart scan that keeps almost arriving
Magnetocardiography reads the faint magnetic field thrown off by the heart's own electrical activity, without touching the patient. It is around sixty years old, it keeps producing evidence that it sees things a standard ECG cannot, and it is still not accepted as a routine clinical tool. The gap between those last two facts is where quantum medicine actually lives.
The clearest account comes from the people who have lived the technique. In a 2023 review in Frontiers in Cardiovascular Medicine, Brisinda, Fenici and Fenici, whose group has worked on magnetocardiography since the early 1980s, write that a large body of research and several clinical trials have shown it reliably supplies diagnostic electrophysiological information beyond what conventional non-invasive electrocardiographic methods provide. Because the sensors sit outside the body, the signal escapes much of the distortion that skin, fat, muscle and bone impose on readings taken at the surface.
So why is it not in the emergency department down the road? The obstacle is noise, and for decades the only answer was a magnetically shielded room that a handful of institutions could afford. That constraint is loosening: optically pumped magnetometers have removed the liquid-helium cooling that chained the method to specialized facilities, and unshielded systems are now being tested against real patients in multicenter trials. The computational side of the field runs on a slower and more honest clock, with its own literature candid that today's noisy qubits leave known algorithms for practical problems out of reach on current machines. Read both clocks together and the useful question is the same for either: what does the accumulated record support today, and where does it stop? Quantum sensing is at the door of the bedside, with a device clearance in hand and multicenter trials under way, while quantum computation in medicine is doing disciplined work well inside a limit its own authors describe out loud. Chest pain drives millions of American emergency-department encounters a year, so the value of getting the first judgment right is considerable, and the value of not overstating the second is just as real. Answer both honestly, one study at a time, and the frontier stops being a slogan and becomes something a clinician, an investor, or a board can actually plan around.